Market Research Logo

Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016

Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016’, provides an overview of the Varicella Zoster (HHV-3) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Varicella Zoster (HHV-3) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
    • The report reviews pipeline therapeutics for Varicella Zoster (HHV-3) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Varicella Zoster (HHV-3) Infections therapeutics and enlists all their major and minor projects
    • The report assesses Varicella Zoster (HHV-3) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Varicella Zoster (HHV-3) Infections
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Varicella Zoster (HHV-3) Infections Overview
    Therapeutics Development
    Pipeline Products for Varicella Zoster (HHV-3) Infections - Overview
    Pipeline Products for Varicella Zoster (HHV-3) Infections - Comparative Analysis
    Varicella Zoster (HHV-3) Infections - Therapeutics under Development by Companies
    Varicella Zoster (HHV-3) Infections - Therapeutics under Investigation by Universities/Institutes
    Varicella Zoster (HHV-3) Infections - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Varicella Zoster (HHV-3) Infections - Products under Development by Companies
    Varicella Zoster (HHV-3) Infections - Products under Investigation by Universities/Institutes
    Varicella Zoster (HHV-3) Infections - Companies Involved in Therapeutics Development
    Astellas Pharma Inc.
    Beijing Minhai Biotechnology Co., Ltd
    Beijing Tiantan Biological Products Co., Ltd.
    ContraVir Pharmaceuticals, Inc.
    Epiphany Biosciences, Inc.
    Foamix Pharmaceuticals Ltd.
    GeneOne Life Science, Inc.
    GlaxoSmithKline Plc
    Green Cross Corporation
    Merck & Co., Inc.
    N & N Pharmaceuticals Inc.
    NAL Pharmaceuticals Ltd.
    NanoViricides, Inc.
    ReceptoPharm, Inc.
    Sinovac Biotech Ltd.
    SK Chemicals Co., Ltd.
    TSRL, Inc.
    XBiotech Inc
    Zydus Cadila Healthcare Limited
    Varicella Zoster (HHV-3) Infections - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (measles + mumps + rubella + varicella) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (measles + rubella + varicella) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    acyclovir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amenamevir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chickenpox vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FV-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GLS-5100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-1437173A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    herpes zoster vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HHV-3 vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    measles + mumps + rubella + varicella vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MG-1111 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Shingles - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NAL-3221 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NAL-3223 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NBP-608 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NN-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RKP-00156 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RPI-78M - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sattabacin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Shingles - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TSR-087 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    V-212 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    valomaciclovir stearate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    varicella zoster vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Varicella Zoster (HHV-3) Infections - Dormant Projects
    Varicella Zoster (HHV-3) Infections - Discontinued Products
    Varicella Zoster (HHV-3) Infections - Product Development Milestones
    Featured News & Press Releases
    Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
    Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
    Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug
    Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
    Oct 27, 2015: GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
    Oct 26, 2015: Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate
    Sep 08, 2015: Clinical trial for Cardiff’s shingles treatment
    Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
    Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
    Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied
    Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
    Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint
    Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
    Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
    Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2016
    Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by Astellas Pharma Inc., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
    aricella Zoster (HHV-3) Infections - Pipeline by Epiphany Biosciences, Inc., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by GeneOne Life Science, Inc., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by Green Cross Corporation, H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by Merck & Co., Inc., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by N & N Pharmaceuticals Inc., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by NanoViricides, Inc., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by ReceptoPharm, Inc., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by Sinovac Biotech Ltd., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by SK Chemicals Co., Ltd., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by TSRL, Inc., H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by XBiotech Inc, H2 2016
    Varicella Zoster (HHV-3) Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Varicella Zoster (HHV-3) Infections - Dormant Projects, H2 2016
    Varicella Zoster (HHV-3) Infections - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2016
    Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report